Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008 : A population-based analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 6, 2013, Pages 606-611

  Mishra, Mark V ^a   Shen, Xinglei ^a   Den, Robert B ^a   Champ, Colin E ^a   Trabulsi, Edouard J ^b   Lallas, Costas D ^b   Gomella, Leonard G ^b   Dicker, Adam P ^a   Showalter, Timothy N ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Active surveillance; Elderly men with prostate cancer; Favorable risk prostate cancer; Patterns of care; SEER

Indexed keywords

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CRYOTHERAPY; DISEASE SURVEILLANCE; GERIATRIC CARE; HUMAN; HYPERTHERMIC THERAPY; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSTATE CANCER; PROSTATECTOMY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; LOGISTIC MODELS; MALE; MARITAL STATUS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SEER PROGRAM; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84892584454     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318261056c     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Galper SL, Chen MH, Catalona WJ, et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006;175:907-912.
4. Albertsen PC. When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol. 2011;50:120-126.
5. Gomella LG, Liu XS, Trabulsi EJ, et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol. 2011;18:5875-5883.
6. Lin K, Lipsitz R, Janakiraman S. Benefits and harms of prostatespecific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:3192-3199.
7. Lin K, Croswell JM, Koenig H, et al. Prostate-specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
8. Caire AA, Sun L, Robertson CN, et al. Public survey and survival data do not support recommendations to discontinue prostatespecific antigen screening in men at age 75. Urology. 2010;75: 1122-1127.
9. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-The-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer. Ann Intern Med. 2012;156:591-595.
10. Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) Research Data (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2011, based on the November 2010 submission.
11. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98:1134-1141.
12. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22: 2141-2149.
13. Roberts CB, Albertsen PC, Shao YH, et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med. 2011;124:235-243.
14. Klotz L, Zhang L, Lam A, et al. Clinical results of long-Term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-131.
15. van den Bergh RC, Roemeling S, Roobol MJ, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol. 2009;55:1-8.
16. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93:1864-1871.
17. Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.
18. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304:2373-2380.
19. Mitchell JM, Sunshine JH. Consequences of physicians' ownership of health care facilities-joint ventures in radiation therapy. N Engl J Med. 1992;327:1497-1501.
20. Schilling PJ. Formation of combined urology and radiation oncology practices: objective data from radiation oncologists for rationale. Am J Clin Oncol. 2011;34:289-291.
21. Albertsen PC, Hanley JA, Penson DF, et al. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol. 2007;177:932-936.
22. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancerspecific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300-4305.
23. Aus G, Pileblad E, Hugosson J. Impact of competing mortality on the cancer-related mortality in localized prostate cancer. Urology. 1995;46:672-675.
24. Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int. 2011;108:1787-1793.
25. Davison BJ, Oliffe JL, Pickles T, et al. Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum. 2009;36:89-96.
26. Pickles T, Ruether JD, Weir L, et al. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100:544-551.
27. Gorin MA, Eldefrawy A, Ekwenna O, et al. Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists. Prostate Cancer Prostatic Dis. 2011;15:177-181.